No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Marker Therapeutics Full Year 2024 Earnings: Misses Expectations
CCORF Maintains Marker Therapeutics(MRKR.US) With Buy Rating, Maintains Target Price $8
Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference
Marker Therapeutics (MRKR) Receives a Buy From Canaccord Genuity
WBB Securities Initiates Marker Therapeutics(MRKR.US) With Buy Rating, Announces Target Price $12.5
WBB Securities Reiterates Strong Buy on Marker Therapeutics, Maintains $12.5 Price Target